Edaravone derivatives containing NO-donor functions.
A new series of polyvalent drugs obtained by joining edaravone with NO-donor moieties is described. All compounds display high antioxidant power together with NO-dependent vasodilator properties. The analysis of a number of molecular descriptors shows that the antioxidant activity, which is tightly linked to the presence of the edaravone substructure, is principally modulated by lipophilicity. These products are potentially useful in the treatment of cardiovascular disorders in which EDRF deficiency and ROS excess are involved.
Chegaev
Konstantin
K
Dipartimento di Scienza e Tecnologia del Farmaco, Universita degli Studi di Torino, Via Pietro Giuria 9, 10125 Torino, Italy.
Cena
Clara
C
Giorgis
Marta
M
Rolando
Barbara
B
Tosco
Paolo
P
Bertinaria
Massimo
M
Fruttero
Roberta
R
Carrupt
Pierre-Alain
PA
Gasco
Alberto
A
D000975:Antioxidants / Q000737:chemistry / Q000494:pharmacology*; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D000077553:Edaravone; D020030:Nitric Oxide Donors / Q000737:chemistry / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000737:chemistry / Q000494:pharmacology*
D000975:Antioxidants; D020030:Nitric Oxide Donors; D014665:Vasodilator Agents; D000077553:Edaravone; D000983:Antipyrine